Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus EP/EC as first-line treatment for extensive-stage small cell lung cancer
ChiCTR2000035043Phase 2Completed
- Sponsor
- Zhengzhou Third People's Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in small cell lung cancer (SCLC), sponsored by Zhengzhou Third People's Hospital. Primary endpoint: progression-free survival. Started Jan 2019; status: completed.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2000035043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035043.